Scilex Pharms patents expiration
1. Gloperba patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10383821 | SCILEX PHARMS | Colchicine drug-to-drug interactions |
Nov, 2036
(12 years from now) | |
| US9907751 | SCILEX PHARMS | Composition and method of use of colchicine oral liquid |
Nov, 2036
(12 years from now) | |
| US10383820 | SCILEX PHARMS | Colchicine drug-to-drug interactions |
Nov, 2036
(12 years from now) | |
| US10226423 | SCILEX PHARMS | Colchicine drug-to-drug interactions |
Dec, 2037
(13 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution
Dosage: SOLUTION;ORAL
How can I launch a generic of GLOPERBA before it's drug patent expiration?
More Information on Dosage
GLOPERBA family patents
2. Ztlido patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925264 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US10765640 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US11278623 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US11786455 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US9283174 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US10765749 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US9931403 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US11793766 | SCILEX PHARMS | Non-aqueous patch for the relief of pain |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 28, 2021 |
Drugs and Companies using LIDOCAINE ingredient
Market Authorisation Date: 28 February, 2018
Treatment: Method for relieving the pain associated with post-herpetic neuralgia
Dosage: PATCH;TOPICAL
How can I launch a generic of ZTLIDO before it's drug patent expiration?
More Information on Dosage
ZTLIDO family patents